However, expression of activated GPIIb/IIIa in response to TRAP stimulation was significantly lower in ECMO patients at all time points compared to controls (e.g., percentage PAC-1 binding day 3 vs. healthy vs. CAD: 6.0 ± 1.5 vs. 56.5 ± 5.8 vs. 34.6 ± 7.5, p < 0.001). This evidence concerns the gene ITGA2B and coronary artery disorder.